Cline Christopher R. — SEC insider filings
SEC reporting owner CIK 1943192. 24 insider filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 24 filings on record, filed 2022-09-01 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 32 legs across 23 filings — 111,015 shares, $4,964,984 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
- Largest priced transaction: sale of 27,473 shares @ $62.00 ($1,703,241) in Travere Therapeutics, Inc., filed 2026-09-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | CHIEF FINANCIAL OFFICER | 24 | — | 32 legs · 111,015 sh · $4,964,984 | 23 |
Insider filings — Cline Christopher R.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 20,000 @ $17.44 · Sale (S): 27,473 @ $62.00 · Sale (S): 20,735 @ $62.61 · Sale (S): 1,900 @ $63.69 · Sale (S): 400 @ $65.31 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2026-09-03 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 642 @ $66.37 | EDGAR |
| 2026-05-06 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 4,250 @ $0 · Sale (S): 2,181 @ $46.65 · Sale (S): 310 @ $43.95 · Grant/award (A): 8,500 (derivative) @ $0 · Option exercise (M): 4,250 (derivative) @ $0 | EDGAR |
| 2026-04-15 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 14,000 @ $0 · Sale (S): 65 @ $28.85 · Sale (S): 9 @ $41.07 · Sale (S): 7,239 @ $41.93 · Sale (S): 1,014 @ $42.61 | EDGAR |
| 2026-02-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 1,635 @ $32.14 · Sale (S): 110 @ $32.90 | EDGAR |
| 2026-02-03 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 28,130 @ $0 · Sale (S): 7,242 @ $32.12 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 20,000 @ $16.23 · Sale (S): 20,000 @ $35.01 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 454 @ $18.20 · Sale (S): 119 @ $19.71 | EDGAR |
| 2025-08-28 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 470 @ $17.31 | EDGAR |
| 2025-05-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 4,920 · Sale (S): 1,784 @ $21.05 · Option exercise (M): 4,920 (derivative) @ $0 | EDGAR |
| 2025-04-14 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 48 @ $13.14 | EDGAR |
| 2025-02-04 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 21,500 @ $0 · Sale (S): 5,192 @ $20.12 · Grant/award (A): 58,000 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 865 @ $18.94 | EDGAR |
| 2024-09-09 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,750 @ $0 · Sale (S): 2,490 @ $11.52 | EDGAR |
| 2024-09-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 514 @ $9.51 | EDGAR |
| 2024-04-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 54 @ $6.74 | EDGAR |
| 2024-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 25,000 @ $0 · Sale (S): 3,818 @ $8.53 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2024-01-25 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 853 @ $9.07 | EDGAR |
| 2023-09-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 457 @ $14.71 | EDGAR |
| 2023-05-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 455 @ $16.59 | EDGAR |
| 2023-04-13 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 47 @ $21.49 | EDGAR |
| 2023-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 20,250 @ $0 · Sale (S): 1,588 @ $21.75 · Grant/award (A): 54,500 (derivative) @ $0 · Grant/award (A): 6,750 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 852 @ $21.90 | EDGAR |
| 2022-09-01 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 5,000 @ $0 · Grant/award (A): 48,000 (derivative) @ $0 · Grant/award (A): 9,840 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2022-05-23 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1943192 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs